Almirall and etherna Enter Into a Multi-Target Alliance to D

BARCELONA, Spain & NIEL, Belgium, December 12, 2023--Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced today a multi-target alliance to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.

Related Keywords

Belgium , United States , Boston , Massachusetts , Barcelona , Comunidad Autonoma De Cataluna , Spain , Spanish , Karl Ziegelbauer , Richard Hayhurst , Bernard Sagaert , Omar Ram , Spanish Stock Exchange , Corporate Communications , Chief Scientific Officer , Noble Purpose , Almirall , Snp , Global Pharmaceutical Company , Skin Diseases , Etherna , Rna , Research And Development , Technology Platform Company ,